Human Chorionic Gonadotropin Market size is forecast to reach $1.18 billion by 2025, growing at a CAGR of 6.91% during the forecast period 2020-2025. Human chorionic gonadotropin (hCG) is a hormone produced by the placenta after implantation. Gonadotropins usually consist of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The presence of hCG is detected in some pregnancy tests, for example, HCG pregnancy strip tests. Some cancerous tumors produce hCG hormone; therefore, elevated levels measured when the patient is not pregnant may lead to a cancer diagnosis and, if high enough, paraneoplastic syndromes, however, it is not known whether this production is a contributing cause, or an effect of carcinogenesis. Rise in demand for infertility treatment products and services, rising incidences of male hypogonadism among the aged population and increase in awareness about infertility treatment are major factors that are driving the market growth in recent years. In addition, major developments by key market players like Ferring and Sanzyme are other factors driving the growth of the market.
Technology – Segment Analysis
Natural Source Extraction held the largest share in the technology segment of Human Chorionic Gonadotropin Market in 2019 and is estimated to grow at a CAGR of 5.29% during the forecast period 2020-2025. Factors that contribute to the growth of this segment are the increasing applications of nature sources extracted gonadotropin in the treatment of infertility disorders among men and women, greater preference by key market players for extracting gonadotropin from natural sources and application in other medical conditions such as cryptorchidism. Recombinant Technology held the second largest share in the market. Recombinant FSH (rFSH) has been shown to be safe and effective in the treatment of fertility disorders. In comparison with the urinary gonadotropin products, human menopausal gonadotropins (HMG), and urinary follitropins (uFSH), rFSH is more potent and better tolerated by patients. Recombinant Technology segment is set to be the fastest growing segment and is set to register the highest CAGR during the forecast period 2020-2025, owing to major investments in technology and innovation for gonadotropin products by key market players.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=502113
Report Price: $ 4500 (Single User License)
Therapeutic Area – Segment Analysis
Female Infertility Treatment segment holds the major share in the application segment of Human Chorionic Gonadotropin Market in 2019. About ten in 100 (6.1 million) women in the U.S. aged 25–44 have difficulty becoming pregnant or staying pregnant, according to the Centers for Disease Control and Prevention. In addition, growing number of fertility clinics and gynecological centers have helped in the market growth of this segment. Male Hypogonadism held the second largest share in the market, owing to higher prevalence of chronic diseases which in turn leads to lower testosterone levels among the middle aged men. Female Infertility segment is forecast to continue growing at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to growing trends in infertility treatment among woman and upgrading lifestyle standards.
Geography – Segment Analysis
North America dominates the geography segment of Human Chorionic Gonadotropin Market with a share of more than 40.7% in 2019, followed by Europe. Growing prevalence of infertility among the adult population, increasing average income of the masses and government initiatives to support technological advancements have helped in the growth of Human Chorionic Gonadotropin Market in this region. Europe held the second place in the geography segment share of the market, owing to increasing health awareness among the masses and technological improvements of infertility treatment methods.
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025. This is owing to growth of the IVF market, entry of new players in the region, increasing incidences of female infertility and growing prevalence of hypogonadism among the geriatric population.
Drivers – Human Chorionic Gonadotropin Market
Rising incidences of male hypogonadism among the aged population
Hypogonadism affects an estimated 4 to 5 million men in the U.S., and although it may occur in men at any age, low testosterone levels are especially common in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. With the growing population at present, combined with increasing prevalence of chronic diseases among a majority of the population, the numbers are anticipated to witness a great surge. As a result, this is set to drive the market growth during the forecast period 2020-2025.
Increase in number of local fertility clinics
The last decade saw the advent of fertility clinics in all regions, mostly locally. Recent publicity given to developments such as gamete intra fallopian transfer (GIFT) and IVF have further increased the demand for infertility treatment. Based on CDC’s 2017 Fertility Clinic Success Rates Report, there were 284,385, infertility treatments performed at 448 reporting clinics in the U.S. during 2017, resulting in 68,908 live births (deliveries of one or more living infants) and 78,052 live born infants. With such large numbers, the market is poised to see significant growth during the forecast period 2020-2025.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – Human Chorionic Gonadotropin Market
Side effects of Human Chorionic Gonadotropin (hCG)
Common side effects of Human Chorionic Gonadotropin (hCG) include headache, irritability, restlessness, fatigue, depression, swelling in the feet, ankles, lowers legs, or hands and appearance of female breasts in men. This creates a negative impact on the demand of hCG among end users. Thus, it is anticipated to hamper the market growth during the forecast period 2020-2025.
Human Chorionic Gonadotropin Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Human Chorionic Gonadotropin Market. In 2019, Human Chorionic Gonadotropin Market share is consolidated by the top players present in the market. Human Chorionic Gonadotropin Market top 10 companies are Bristol Myers Squibb Company, Merck & Co., Inc., Ferring Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Lee BioSolutions Inc., LUPIN, Sanzyme, Scripps Laboratories and Cigna among others.
In January 2019, Ferring acquired exclusive U.S. commercialization rights for generic Ganirelix Acetate Injection for the prevention of premature ovulation in women undergoing fertility treatment.
In June 2018, Sanzyme entered into an agreement with Inolife for Gonadotropin Kinetics and Bio-Equivalence Validation.
In May 2020, Tolmar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its drug application for FENSOLVI® (leuprolide acetate) for injectable suspension for the treatment of pediatric patients two years of age and older with central (gonadotropin-dependent) precocious puberty (CPP).
North America dominated the Human Chorionic Gonadotropin Market in the year 2019 owing to rising prevalence of infertility among both genders of the adult population, increasing healthcare affordability of the majority population and government initiatives to support technological advancements. The Human Chorionic Gonadotropin Market scope for different regions will be provided in the final report.
Increase in number of local fertility clinics, presence of advanced technological treatments of infertility, technological advancements in Gonadotropin Market and favorable government policies for fertility provision services have helped in significant growth of Human Chorionic Gonadotropin Market. Increasing investments for economical and cost effective infertility treatment by key market players and various government agencies in upcoming years is estimated to drive the industry growth during the forecast period 2020-2025.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Human Chorionic Gonadotropin Market report.
Side effects of Human Chorionic Gonadotropin (hCG) is anticipated to hamper the market growth of the Human Chorionic Gonadotropin Industry.
A. Human Growth Hormone Market
B. Remicade Biosimilar Market
About IndustryARC:IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to firstname.lastname@example.org to discuss more about our consulting services.